The core activity of Adagene is the discovery and development of therapeutic antibodies for the treatment of cancer. The company focuses on developing antibodies with novel mechanisms of action (MOAs) and utilizes its own technology platform, which is based on the dynamic precision of antibodies. Adagene develops antibodies for various applications, including cancer immunotherapy, and has partnerships with global companies to leverage its technology and develop new treatment options.